Abstract 1578P
Background
Despite the beneficial findings from different clinical trials, targeted immunotherapy is still debated in advanced gastric cancer care. Immune checkpoint inhibitors (ICIs) of programmed cell death protein 1 (PD-1) have emerged as a promising therapeutic option, demonstrating clinical activity in gastric cancer. This study aims to analyze the impact of PD-1 inhibition overall survival of a large-scale series of patients treated for metastatic gastric cancer.
Methods
A retrospective study was designed by using TriNetX Platform for a large-scale search of patients with metastatic gastric cancer, who underwent immunotherapy at large healthcare organizations collaborating through TriNetX-mediated network at both European (EMEA collaborative group) and international (GLOBAL) levels. Propensity score matching was used to balance these cohorts against the cohort of metastatic gastric cancer patients not treated with PD-1 inhibitors, to remove possible confounding effect of age and gender. Kaplan Meier analysis was used to compare the 2-year overall survival of these two cohorts, after propensity score matching was used.
Results
From a total of 15.318 patients affected by metastatic gastric cancer, a cohort of 1.425 patients treated with PD-1 inhibitors was identified, including 1.372 from TriNetX healthcare organization network at a global level (TNX-GLOBAL) and 53 from the EMEA group (TNX-EMEA). When compared to the propensity score matched control patient’s cohort with no PD-1 treatment, anti-PD-1 treated patients had significantly better overall survival in both TNX-GLOBAL, 44.73% vs 41.26% (p<0.01), and in TNX-EMEA, 39.31% vs 21.47% (p<0.01).
Conclusions
The evidence from the present retrospective cohort study using real-world data from TNX-GLOBAL and TNX-EMEA collaborative networks created the unique opportunity to analyze a large-scale series of patients with metastatic gastric cancer. Positive effects of anti-PD-1-targeted therapy on survival of such a frail cohort demonstrated the clinical relevance of prevalence of PD-1 expression and supported the effectiveness of new therapies based on ICI's for metastatic disease. Given these results, further studies on the role of ICI’s also in perioperative setting are awaited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Ospedale San Raffaele.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22